No serious systemic side effects have been documented in peer-reviewed studies at therapeutic doses
In the literature, there appear to be ten other cases of colonic ischemia associated with GLP-1 agonist or GLP-1/GIP dual agonist use (Table 3) [12,13,14,15,16,17,18,19,20,21]
It was tested by Aminos Analytics and is 0.7 EU/mL
Initial consultations are followed by weekly check-ins for monitoring and support
guidance for repeated-entry vials points to a 28-day window unless the label states another period, and that opened-vial window cannot go past the original expiration date
We strongly recommend consulting a healthcare professional before use and never exceeding recommended starting doses